Urogen Pharma Ltd
URGN20.820USD
0.000
收盤 11/03, 16:00（美東）報價延遲15分鐘
961.87M總市值
虧損本益比TTM
關於 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. 是一家位於以色列的生物製藥公司。該公司致力於爲癌症和泌尿系統疾病提供解決方案。UroGen 開發了 RTGelTM 逆向熱凝膠，這是一種專有的緩釋水凝膠平臺技術，有可能改善現有藥物的治療效果。其主要候選產品包括 MitoGel 和 VesiGel，採用其專有的逆向熱觸發水凝膠或 RTGel 技術配製而成。MiroGel (UGN-101) 是化療藥物絲裂黴素 C 的緩釋製劑，用於治療低級別上尿路上皮癌，這是一種上尿路上皮癌。VesiGel (UGN-102) 是高劑量絲裂黴素 C 的緩釋製劑，用於治療低級別非肌層浸潤性膀胱癌 (LG-NMIBC)。
Urogen Pharma Ltd簡介
公司代碼URGN
公司名稱Urogen Pharma Ltd
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
員工數量235
證券類型Ordinary Share
年結日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ Global Market Consolidated
國家Israel
郵編4365007
電話97297707601
網址https://www.urogen.com/
公司代碼URGN
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Urogen Pharma Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
Jelmyto
24.21M
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Jelmyto
24.21M
0.00%
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
持股股東
持股股東
佔比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
股東類型
持股股東
佔比
Hedge Fund
29.41%
Research Firm
21.32%
Investment Advisor/Hedge Fund
20.22%
Investment Advisor
17.19%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.10%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
309
45.30M
97.92%
-6.91M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
4.54M
9.82%
+709.10K
+18.49%
Jun 30, 2025
TD Securities, Inc.
3.19M
6.9%
+1.44M
+82.40%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.33M
5.04%
+2.33M
--
Aug 05, 2025
Jefferies LLC
2.20M
4.75%
+1.38M
+169.90%
Jun 30, 2025
Soleus Capital Management, L.P.
2.19M
4.72%
+2.19M
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.11M
4.56%
-34.56K
-1.61%
Jun 30, 2025
SilverArc Capital Management, LLC
2.02M
4.37%
+641.32K
+46.43%
Jun 30, 2025
Pontifax Venture Capital
1.49M
3.21%
-1.00
-0.00%
Mar 14, 2024
Morgan Stanley & Co. LLC
1.47M
3.19%
+1.27M
+633.13%
Jun 30, 2025
Arkin Communication, Ltd.
1.37M
2.96%
--
--
Feb 22, 2024
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
ARK Israel Innovative Technology ETF
2.13%
Tema Oncology ETF
1.43%
ALPS Medical Breakthroughs ETF
0.55%
Hypatia Women CEO ETF
0.19%
iShares Micro-Cap ETF
0.16%
Vanguard US Momentum Factor ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
查看更多
ARK Israel Innovative Technology ETF
佔比2.13%
Tema Oncology ETF
佔比1.43%
ALPS Medical Breakthroughs ETF
佔比0.55%
Hypatia Women CEO ETF
佔比0.19%
iShares Micro-Cap ETF
佔比0.16%
Vanguard US Momentum Factor ETF
佔比0.11%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
iShares Biotechnology ETF
佔比0.07%
Fidelity Enhanced Small Cap ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
